) because the trial was small and
the results had not been replicated in other trials with a longer
follow up period.
The Society’s committee charged with developing
guidelines for atherosclerotic occlusive disease of the lower
extremities has decided to strike recommendation 4.11 based
on the current state of evidence after retraction of this trial.
The committee notes that many patients with IC may
still beneﬁt from angiotensin-converting enzyme inhibitors
